New Zealand Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the New Zealand Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

New Zealand Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: New Zealand's updated Health Strategy draft will see limited improvement to the challenging business environment for innovative drugmakers. Cost minimisation continues to be a key aspect of the approach adopted, with the Pharmaceutical Management Agency maintaining its dominant role in curbing pharmaceutical spending. Nonetheless, there will be opportunities for other segments of the health industry, such as telecare, which is poised to play a critical role in enabling New Zealand to achieve its objectives.

Headline Expenditure Forecasts

  • Pharmaceuticals : NZD1.45bn (USD1.20bn) in 2014 to NZD1.48bn (USD1.04bn) in 2015; 2.0% in local currency terms and -11.4% in US dollar terms. Forecast unchanged from last quarter.

  • Healthcare: NZD22.57bn (USD18.72bn) in 2014 to NZD23.10bn (USD16.17bn) in 2015; 2.4% in local currency terms and -13.6% in US dollar terms. Forecast in US dollar terms with a slight downward revision due to currency effects.

Headline Pharmaceuticals & Healthcare Forecasts (New Zealand 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 1.166 1.203 1.036 0.982 0.926 0.946 0.967
Pharmaceutical sales, % of GDP 0.63 0.61 0.61 0.60 0.58 0.57 0.56
Pharmaceutical sales, % of health expenditure 6.4 6.4 6.4 6.4 6.4 6.4 6.3
Health spending, USDbn 18.091 18.718 16.170 15.373 14.533 14.890 15.262

Risk/Reward Index

In BMI's Q1 2016 Pharmaceutical Risk/Reward Index (RRIs), New Zealand, sustaining its place from Q4 2015, is ranked ninth out of the 19 markets in the matrix. With a score of 53.1 out of 100, unchanged from the previous three quarters, the country remained just above the regional average of 52.1. A strong and predictable environment of low operating risks are weighed down by a small market and low potential for growth relative to other markets in the region.

Latest Updates

  • In October 2015, New Zealand along with the other 11 member states of the Trans-Pacific Partnership trade agreement concluded their negotiations. This trade deal affects many industries, including healthcare and regulatory data protection of biologics.

  • In November 2015, New Zealand and China established the Joint Centre for Biomedicine, a collaboration between the University of Auckland and the Chinese academy of sciences.

BMI Economic View

The New Zealand economy continues to suffer from the weakening dairy sector, and we forecast real GDP growth to slow to 2.4% in 2015, versus 3.3% in 2014. Meanwhile, we expect the New Zealand dollar to continue heading lower over the medium term, undermined by falling real interest rates as the economy continues to slow amid a terms of trade decline.

BMI Political View

New Zealand's revised health and safety bill, while reflecting a political compromise with the powerful dairy lobby, will go some way in improving workplace health and safety in the country. Despite an initial increase in production costs, the country's business environment is unlikely to be adversely impacted given the boost to long-term productivity as workplace accidents decline.

BMI Industry View
7
SWOT
9
SWOT
9
Political
11
Economic
12
Operational Risk
14
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (New Zealand 2011-2019)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (New Zealand 2011-2019)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
20
OTC Medicine Market Forecast
21
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
22
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (New Zealand 2011-2019)
25
Pharmaceutical Trade Forecast
25
Table: Pharmaceutical Trade Data And Forecasts (New Zealand 2013-2019)
26
Key Risks To BMI's Forecast Scenario
26
Macroeconomic Forecasts
28
Economic Analysis
28
Table: Economic Activity (New Zealand 2010-2019)
31
Industry Risk Reward Ratings
32
Asia Pacific Risk/Reward - Q4 2015
32
New Zealand Risk/Reward Index
38
Rewards
38
Risks
38
Market Overview
40
Industry Trends And Developments
41
Epidemiology
41
Healthcare Sector
42
Infrastructure
43
Table: Healthcare Resources (New Zealand 2009-2014)
43
Table: Healthcare Activity (New Zealand 2009-2014)
43
Table: Healthcare Personnel (New Zealand 2009-2014)
44
Distribution Channels
44
Table: Pharmacybrands Stores By Company & Region, 2010
46
Research And Development
47
Clinical Trials Sector
47
Regulatory Development
49
Regulatory Regime
49
Intellectual Property Regime
49
Pricing & Reimbursement
50
Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn), 2005-2010
55
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
56
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
57
Recent Regulatory Developments
57
Competitive Landscape
59
Company Profile
60
Southern Cross Healthcare Group
60
Douglas Pharmaceuticals
66
New Zealand Pharmaceuticals
69
Pfizer New Zealand
72
Demographic Forecast
74
Table: Population Headline Indicators (New Zealand 1990-2025)
75
Table: Key Population Ratios (New Zealand 1990-2025)
75
Table: Urban/Rural Population & Life Expectancy (New Zealand 1990-2025)
76
Table: Population By Age Group (New Zealand 1990-2025)
76
Table: Population By Age Group % (New Zealand 1990-2025)
77
Glossary
79
Methodology
81
Pharmaceutical Expenditure Forecast Model
81
Healthcare Expenditure Forecast Model
81
Notes On Methodology
82
Risk/Reward Index Methodology
83
Index Overview
84
Table: Pharmaceutical Risk/Reward Index Indicators
84
Indicator Weightings
85

The New Zealand Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's New Zealand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the New Zealand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for New Zealand, to test other views - a key input for successful budgeting and strategic business planning in the New Zealand pharmaceutical and healthcare market.
  • Target business opportunities and risks in the New Zealand pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in New Zealand.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.